O Myung-don, Chair of the Central Clinical Committee, "80% of COVID-19 cases are mild"

[Asia Economy Reporter Oh Ju-yeon] The Central Clinical Committee, composed of primary physicians of confirmed COVID-19 patients, announced on the 23rd that "even if infected with COVID-19, 80% of cases pass mildly, so there is no great need to worry about treatments."

On this day, Oh Myung-don, chairman of the Central Clinical Committee (professor of infectious diseases at Seoul National University College of Medicine), stated this at a press conference titled 'Understanding the COVID-19 Pandemic and Response Strategies' held at the National Medical Center.

Chairman Oh said, "Even if pneumonia occurs, if patients are hospitalized, receive oxygen therapy, and are stabilized, they seem to recover more easily than with other types of pneumonia," adding, "I want to emphasize once again that since 80% of COVID-19 infections pass mildly, there is no need to worry even if there is no special treatment."

He continued, "Even patients who underwent ECMO appear to recover after about one to two weeks of supportive treatment, even without the power of antiviral drugs."

Currently, since there are no clear vaccines or treatments for COVID-19, antiviral drugs used for treating AIDS, Ebola, etc., are administered, or symptomatic treatments are provided to alleviate symptoms.

The 'Expert Recommendations on COVID-19 Drug Treatment,' jointly announced by the Korean Society of Infectious Diseases, the Korean Society for Antimicrobial Therapy, and the Korean Society of Pediatric Infectious Diseases, states that antiviral therapies such as the AIDS treatment drug Kaletra, the malaria treatment drug chloroquine, a combination of Kaletra and interferon, the Ebola treatment drug remdesivir, a combination of ribavirin and Kaletra, or a combination of ribavirin and interferon (ribavirin monotherapy is not recommended) are worth considering.

This content was produced with the assistance of AI translation services.